2 HIV drugs from Gilead's Stribild fail to win FDA approval as standalones

04/30/2013 | MedCityNews.com

The FDA turned down Gilead Sciences' regulatory applications for elvitegravir and cobicistat as standalone treatments for HIV, citing problems in certain quality testing procedures. The two drugs are included in Gilead's 4-in-1 HIV pill Stribild, which was approved by the FDA last year. Gilead says it is working with the agency to address the issues mentioned in the rejection letter.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN